Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 11/7/2025

Reversal of Apixaban

Introduction to Reversal Strategies

  • The American College of Cardiology recommends andexanet alfa as the first-line specific reversal agent for life-threatening bleeding in patients taking apixaban, with dosing of either 400 mg IV bolus over 15 minutes followed by 480 mg infusion over 2 hours (low dose) or 800 mg IV bolus over 30 minutes followed by 960 mg infusion over 2 hours (high dose), depending on the timing and amount of the last apixaban dose 1, 2, 3

Indications for Reversal

  • Reversal should be initiated for life-threatening bleeding, including intracranial hemorrhage, symptomatic or expanding extradural hemorrhage, or uncontrollable hemorrhage 4, 3
  • Reversal should be initiated for bleeding in critical organs or closed spaces, including intraspinal, intraocular, pericardial, pulmonary, retroperitoneal, or intramuscular with compartment syndrome 4, 3
  • Reversal should be initiated for severe bleeding with hemodynamic instability or causing hemoglobin decrease ≥2 g/dL or requiring ≥2 units of RBCs 2
  • Reversal should be initiated for emergency surgery with high bleeding risk when apixaban cannot be cleared in time 5

Primary Reversal Strategy: Andexanet Alfa

  • Andexanet alfa is a recombinant modified factor Xa protein that acts as a decoy, binding apixaban with high affinity and preventing it from inhibiting endogenous factor Xa, rapidly reducing anti-factor Xa activity by 93-94% within 2-5 minutes of administration 6, 5, 1
  • The choice between low and high dose depends on the timing of the last apixaban dose and the dose amount taken, with lower doses needed for apixaban compared to rivaroxaban because drug concentrations are lower with twice-daily dosing 6
  • In the ANNEXA-4 study, 80% of patients achieved excellent or good hemostatic efficacy at 12 hours after andexanet administration 1

Alternative Reversal: 4-Factor Prothrombin Complex Concentrate (Kcentra)

  • When andexanet alfa is unavailable, administer 4-factor PCC (Kcentra) at 50 U/kg IV (maximum 4,000 units), as recommended by the American College of Cardiology as the alternative strategy 2

Laboratory Assessment

  • Anti-factor Xa activity assays are preferred for quantifying apixaban levels, with a threshold of >50 ng/mL considered clinically significant for serious bleeding 2, 3
  • Do not use PT, INR, aPTT, or anti-FXa activity to monitor the effectiveness of PCCs when used for reversal 4

Critical Safety Considerations

  • Thrombotic events occur in approximately 10% of patients within 30 days of receiving andexanet alfa, emphasizing the need for prompt resumption of anticoagulation after bleeding control 2, 5, 3, 1
  • The reversal effect of andexanet alfa is transient, with anti-factor Xa activity returning toward baseline approximately 2 hours after infusion completion 5, 3

Adjunctive Measures

  • Tranexamic acid can be considered as adjunctive therapy to support hemostasis, though it does not directly reverse the anticoagulant effect 2

REFERENCES

2

Reversal of Apixaban with Kcentra [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

3

Reversal of Apixaban in Life-Threatening Bleeding [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

5

Reversal Agents for Rivaroxaban-Associated Bleeding [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025